Prognostic significance of metabolic parameters measured by 18F-FDG PET/CT in limited-stage small-cell lung carcinoma

[1] Azad A(2010)High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer Mol Imaging Biol 12 443-451

[2] Chionh F(2011)Quality of life assessment as a predictor of survival in non-small cell lung cancer BMC Cancer 11 353-1620

[3] Scott AM(2004)Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer Eur J Nucl Med Mol Imaging 31 1614-715

[4] Lee ST(2012)18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging J Nucl Med 53 709-3494

[5] Berlangieri SU(2005)Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer J Clin Oncol 23 3488-22638

[6] White S(2016)MicroRNA-related polymorphisms in apoptosis pathway genes are predictive of clinical outcome in patients with limited disease small cell lung cancer Oncotarget 7 22632-1917

[7] Mitchell PL(2003)Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer J Nucl Med 44 1911-359

[8] Braun DP(1993)The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas J Nucl Med 34 355-613

[9] Gupta D(2006)Consideration of serum glucose levels during malignant mediastinal lymph node detection in non-small-cell lung cancer by FDG-PET J Surg Oncol 94 607-2432

[10] Staren ED(2009)High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer Clin Cancer Res 15 2426-2794

[1] Azad A(2010)High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer Mol Imaging Biol 12 443-451

[2] Chionh F(2011)Quality of life assessment as a predictor of survival in non-small cell lung cancer BMC Cancer 11 353-1620

[3] Scott AM(2004)Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer Eur J Nucl Med Mol Imaging 31 1614-715

[4] Lee ST(2012)18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging J Nucl Med 53 709-3494

[5] Berlangieri SU(2005)Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer J Clin Oncol 23 3488-22638

[6] White S(2016)MicroRNA-related polymorphisms in apoptosis pathway genes are predictive of clinical outcome in patients with limited disease small cell lung cancer Oncotarget 7 22632-1917

[7] Mitchell PL(2003)Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer J Nucl Med 44 1911-359

[8] Braun DP(1993)The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas J Nucl Med 34 355-613

[9] Gupta D(2006)Consideration of serum glucose levels during malignant mediastinal lymph node detection in non-small-cell lung cancer by FDG-PET J Surg Oncol 94 607-2432

[10] Staren ED(2009)High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer Clin Cancer Res 15 2426-2794